1ml vial of semaglutide Semaglutide: Injection Home Kit – NativeMed Semaglutide Weight Loss Treatment: GLP-1

This precision is one of the strongest arguments for vial-based dosing, especially during the critical early phases when finding your personal tolerance threshold matters most

SELECT Trial: The Evidence for CV Coverage The SELECT trial (published in NEJM, November 2023) demonstrated that Wegovy reduces cardiovascular events: [27] 20% reduction in major adverse cardiovascular events (MACE) Includes heart attacks, strokes, and cardiovascular death 17,604 participants followed for ~3.3 years All participants had established cardiovascular disease plus obesity/overweight Typical Plan Coverage Criteria for CV Indication Medicare plans that cover Wegovy for cardiovascular risk reduction typically require: Clinical Criteria Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) BMI (body mass index) 27 kg/m No Type 2 diabetes (or T2D not adequately controlled) Concurrent lifestyle modifications (diet and exercise) Required Documentation Cardiology records documenting established CVD Current BMI (height and weight within last 30 days) Letter of Medical Necessity from cardiologist or primary care provider Documentation of lifestyle modification attempts ICD-10 Codes for CV vs

HCPCS code J3420 is used to report the injection of vitamin B-12 cyanocobalamin, up to 1000 mcg, administered by a non-oral route such as intramuscular or subcutaneous injection

E.ShimadaK.SkoutaR.ViswanathanV

Its taking all the worry out of the food going in. (P8, female, diabetes)

The increased gallstone risk may be attributable to two mechanisms: the rapid and substantial weight loss these medications facilitate, and potentially direct effects of GLP-1 agonists on reducing gallbladder motility and emptying